FT/路透：GE医疗洽谈以最高约10亿美元收购私有放射性药物公司Sofie Biosciences，双方均未置评

GE HealthCare is said to be on the cusp of buying out radiopharmaceutical developer Sofie Biosciences, according to a report by the Financial Times.
Citing “people familiar with the matter,” the FT said GE could pay out as much as $1 billion for the deal, which could come as soon as this coming week. Neither company has so far commented on the report.
Sofie Biosciences, a 20-year-old Dulles, Virginia-based based medtech, works on creating specialized chemicals used in scanning machines that looks for cancers.
This deal, should it go ahead, would help bolster GE’s pharma diagnostics business. It’s currently one of the major manufacturers of medical imaging equipment, including MRI, CT and PET scanners.
Back in April, GE said it was cutting its profit outlook while also making structural changes to its business and executive teams.
This included a “strategic evolution of its operations and executive leadership team,” which created a new business segment, Advanced Imaging Solutions, by merging its former imaging and ultrasound units under one umbrella, led by Phil Rackliffe.
GE HealthCare’s two formerly largest segments were combined to “create a more focused and connected end-to-end imaging ecosystem,” the company said at the time.
In July, GE then said it was performing “a comprehensive strategic review” of its Patient Care Solutions business amid ongoing “operational fulfillment issues and supply chain constraints.”